CDTX Stock: Cidara Therapeutics, Inc. Stock Price, Analysis & Insights
Get live cdtx stock price $217.71, comprehensive Cidara Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time cdtx stock data and investment insights.
Loading chart...
Company Overview
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Company Information
- CEO
- Jeffrey L. Stein
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
Contact Information
- Website
- https://www.cidara.com
- Address
- 6310 Nancy Ridge Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.55)
Business Model & Strategy
Cidara Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Jeffrey L. Stein, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Cidara Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 5.5 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Cidara Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Cidara Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Cidara Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Cidara Therapeutics, Inc.
- ⚠Investors should consider how Cidara Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
5.52B
P/E Ratio
-19.42
Beta
1.55
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 5.52B market capitalization
- Trading Volume: 17.29M shares traded today
- Price Range: 52-week range of $14.33 - $218.85
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. (CDTX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 5.52B, the company represents a significant player in its market. The stock is currently trading at $217.71 with a positivedaily change of 105.41%.
The company's 38 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -19.42, beta of 1.55, and 52-week price range from $14.33 to $218.85when evaluating investment opportunities.
Why Invest in Cidara Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Jeffrey L. Stein
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.